Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707295 | 0.90 | MAPT (0.42) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL9103782 | 0.90 | MAPT (0.48) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL3699317 | 0.90 | MAPT (0.44) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL9105309 | 0.89 | MAPT (0.47) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL9107165 | 0.89 | MAPT (0.47) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL3694999 | 0.89 | MAPT (0.49) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL3694901 | 0.88 | MAPT (0.47) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL9107477 | 0.88 | MAPT (0.49) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL9108290 | 0.86 | MAPT (0.45) | MAPTTP53KMT2AMEN1ADAM17 | |
| SCHEMBL3704317 | 0.86 | MAPT (0.40) | MAPTTP53KMT2AMEN1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| EP-2460798-A2 | APAF-1 INHIBITOR COMPOUNDS | Laboratorios SALVAT, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | MAPT 4448/4885TP53 336/4885KMT2A 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.